Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 08, 2022 11:49am
177 Views
Post# 34296120

RE:RE:RE:RE:RE:RE:RE:RE:RE:Something big is likely in the works

RE:RE:RE:RE:RE:RE:RE:RE:RE:Something big is likely in the worksI agree a buyout is not the most likely scenario right now but I would not be shocked if a larger pharma took a serious stake in TH as a way of laying claim to it early in case things work out well on the cancer and/or NASH front.It does not take too much ingenuity to conclude that larger pharma may be the very cashed flow positive Pfizer that has a zillion connections already to TH but, who knows, maybe it is a Chinese company?

As for the meeting with the large shareholders, there is no known agenda. Which pretty much tells us that events between now and then will likely provide the agenda. But an alternative explanationis they are just doing the rounds of the grumpy, long term shareholders to try and make sure there is a better outcome on the next board vote - seeing some board members get a low number of votes is not something that likely went over well in the boardroom and Paul is no doubt anxious to not have a replay of that. So, it makes sense to meet with the offended parties and bring them back onside. So, that may be all that it is.

Last I heard, the speakers from the company are Paul and Philippe. Christian was at best a maybe but it sounded like it was going to be a stretch for him to make it. I know the shareholders would love it if he came as he has a lot of credibility with them. I am sure he is a very busy man right about now - in fact he has been a very busy man for a long time and we have a lot to be thankful for that he has poured himself into his work in a big way for such a long time. 

If Paul and Philippe show up at a meeting with shareholders, they will be talking about the business, you can be sure about that. An offering may be part of what is going down, and that would not be too surprising, but I would also not be surprised if they raised the needed cash via a partnership and/or an ownership stake being purchased by a larger pharma company, again Pfizer being the most likely. 

As I said yesterday, the weight of the evidence leans heavily in the direction of something good being announced soon. That is no guarantee that we will be happy with the outcome however. For example, if they do sell an equity blocking stake to a larger pharma, at what price do they transact that? Ideally, we don't want any blocking stake being sold as we are hoping for a good outcomein cancer (and maybe even NASH) and would prefer a competitive bidding contest for TH at later date and a much higher price. So, we could be simultaneously happy and ticked off. It is TH, after all, so that may be what we should be thinking until proven otherwise! 

palinc2000 wrote:

Most of The positions advertised dont seem to have been filled so that would not be a problem but I dont think that a buyout is very likely at this stage...I am still wondering why a Meeting has been called with apparently no known agenda and no list of all participants.It cant be about running the business or discussing material info not yet disclosed to the public.... That leaves the other iption which is raising capital by way of a Private Placement .... hard to comment on that without knowing the terms ..
 

 

Bucknelly21 wrote: Do you really think they would do all that hiring to just settle for a buyout?

 

 



<< Previous
Bullboard Posts
Next >>